Amneal Pharmaceuticals (AMRX) Tops Q3 EPS by 4c, Revenues Beat; Raises FY20 Revenue Guidance Above Consensus

Amneal Pharmaceuticals (: AMRX) reported Q3 EPS of $0.16, $0.04 better than the analyst estimate of $0.12. Revenue for the quarter came in at $519 million versus the consensus estimate of $482.11 million.

“Amneal delivered another strong quarter, providing further evidence that our Amneal 2.0 strategy is positioning the company for sustained growth,” said Chirag and Chintu Patel, Co-Chief Executive Officers. “While the COVID pandemic continues to affect some aspects of the business, we continue to focus on execution, improving the productivity of our operations and building a strong, diverse platform of generic and specialty pharmaceuticals. We appreciate the hard work of our employees in achieving these results and supporting Amneal’s mission of bringing affordable medicines to patients.”

GUIDANCE:

Amneal Pharmaceuticals sees FY2020 revenue of $1.95-2 billion, versus the consensus of $1.93 billion.

For earnings history and earnings-related data on Amneal Pharmaceuticals (AMRX) click here.

You May Also Be Interested In

• Primoris cuts 2026 outlook on renewables cost overruns, COO exits
• Guardian Pharmacy names new COO and CFO, effective July 2026
• A.O. Smith executive chairman to retire, CEO to assume chairman role